NASDAQ$IDYA
IDEAYA Biosciences Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Announced financial results for the second quarter ended June 30, 2024 and provided a business update.
IDEAYA Biosciences reported $952.7 million in cash, cash equivalents and marketable securities as of June 30, 2024. Significant progress was made advancing four potential first-in-class precision medicine oncology clinical programs. Preliminary clinical proof of concept data was presented for IDE397 monotherapy in MTAP-deletion urothelial and lung cancer.
- Darovasertib achieved triple-digit enrollment in Phase 2/3 trial in 1L HLA-A2*02:01(-) MUM and >50 patients enrolled in Phase 2 neoadjuvant UM study
- Demonstrated preliminary proof-of-concept for IDE397 in MTAP urothelial and lung cancer with 1 PR awaiting confirmation confirmed and 1 additional PR still awaiting confirmation
- IDEAYA financially budgeted to support its obligations for target IDE397 / AMG 193 clinical combination expansion in NSCLC in consultation with Amgen
- IDEAYA plans to host an Investor R&D Day in Q4 2024
Headline financials
Revenue & EPS history
IDEAYA · Revenue · Quarterly
$0
Revenue by segment
IDEAYA · $8.04M total across 1 segment · Q3 2023
- Collaboration Revenue$8.04M—100.0%
Forward guidance
IDEAYA is targeting several milestones in the second half of 2024 across its clinical programs.
Tailwinds
- Targeting Phase 2 neoadjuvant UM data update in H2'24
- Targeting initial IDE161 Ph 1/2 expansion in H2'24
- Targeting Phase 1 FPI for IDE161 in combination with KEYTRUDA in endometrial cancer in H2'24
- Targeting Werner IND in H2'24
- Targeting MTAP and KAT6 pathway DCs in H2'24
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
+1.4%
Avg return
Earnings day
+2.1%
Avg return
5 days after
+6.7%
Avg return
30 days after
52%
14 / 27 earnings
Positive
+40.5%
Q3 2019
Best reaction
-31.4%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.3% | -1.9% | +1.2% | |
| Q4 2025 | +1.6% | +5.6% | +7.7% | |
| Q3 2025 | -2.7% | -3.6% | +14.8% | |
| Q1 2025 | +2.9% | +10.6% | +28.1% | |
| Q4 2024 | -5.4% | -6.9% | -15.4% | |
| Q3 2024 | +3.4% | +9.4% | -0.9% | |
| Q2 2024 | -3.1% | +2.4% | +1.0% | |
| Q1 2024 | -3.9% | -4.5% | -8.0% | |
| Q4 2023 | -6.0% | -2.7% | -3.2% | |
| Q3 2023 | +6.9% | +1.6% | +8.1% | |
| Q2 2023 | +1.2% | +3.3% | +12.9% | |
| Q1 2023 | +15.6% | +10.2% | +31.5% | |
| Q4 2022 | +2.1% | -8.7% | -16.0% | |
| Q3 2022 | -3.4% | -1.8% | -2.5% | |
| Q2 2022 | -31.4% | -34.8% | -20.1% | |
| Q1 2022 | +13.0% | +26.4% | +48.4% | |
| Q4 2021 | -2.2% | +3.8% | -11.1% | |
| Q3 2021 | +3.9% | +0.8% | -4.1% | |
| Q2 2021 | -3.5% | +1.0% | +14.1% | |
| Q1 2021 | +7.8% | +1.7% | +12.5% | |
| Q4 2020 | -8.2% | -2.8% | -15.9% | |
| Q3 2020 | +2.5% | +6.3% | +9.3% | |
| Q2 2020 | -1.2% | -1.7% | +4.8% | |
| Q1 2020 | -9.4% | -0.6% | -5.3% | |
| Q4 2019 | +13.6% | +14.9% | +40.8% | |
| Q3 2019 | +40.5% | +30.6% | +29.6% | |
| Q2 2019 | +6.0% | -1.5% | +19.6% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro